Quidel Corporation (QDEL) Releases Earnings Results, Misses Expectations By $-0.03 EPS

Quidel Corporation (QDEL) reported quarterly earnings results on Wednesday, Apr-27-2016. The company reported $0.02 earnings per share for the quarter, missing the analyst consensus estimate by $-0.03. Analysts had a consensus of $0.05. The company posted revenue of $50.30 million in the period, compared to analysts expectations of $50.61 million. The company’s revenue was down -18.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 EPS.

Many Wall Street Analysts have commented on Quidel Corporation. Shares were Reiterated by Barclays on Feb 18, 2016 to “Overweight” and Lowered the Price Target to $ 22 from a previous price target of $28 .Shares were Downgraded by Canaccord Genuity on Feb 9, 2016 to ” Hold” and Lowered the Price Target to $ 18 from a previous price target of $22 .

Quidel Corporation opened for trading at $18.95 and hit $19.25 on the upside on Friday, eventually ending the session at $19.24, with a gain of 1.96% or 0.37 points. The heightened volatility saw the trading volume jump to 1,05,338 shares. Company has a market cap of $621 M.

In a different news, on Feb 23, 2016, Douglas C Bryant (CEO) purchased 3,700 shares at $13.91 per share price. According to the SEC, on Dec 3, 2015, John Tamerius (SVP, Strat & Ext Affairs) sold 21,109 shares at $21.83 per share price.

Quidel Corporation is engaged in the development manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases women’s health and gastrointestinal diseases. The Company sells its products directly to end users and distributors in each case for professional use in physician offices hospitals clinical laboratories reference laboratories universities retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions including infectious diseases women’s health autoimmune diseases bone health thyroid diseases and fecal occult blood.

Quidel Corporation

Leave a Reply

Quidel Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Quidel Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.